Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous Tcm Cellular Immunotherapy in ICC After Radical Resection
NCT03820310Phase 2Recruiting
- Sponsor
- Newish Technology (Beijing) Co., Ltd.
- Start
- May 2018
- Primary completion
- Jun 2025
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in intrahepatic cholangiocarcinoma (ICC) (2 arms), sponsored by Newish Technology (Beijing) Co., Ltd. Primary endpoints: Progression Free Survival at 24 months and Two-year survival at 24 months. Started May 2018; status: recruiting.
02
Conditions
intrahepatic cholangiocarcinoma (ICC)
Beyond the preview
Go deeper on NCT03820310.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03820310.